Business
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.Builds toward the establishment of
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6EHDfoEoG7q5NqehvIMhgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MQ--/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/6EHDfoEoG7q5NqehvIMhgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MQ--/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.","length":341,"tagName":"p"}]},{"val":[{"type":"text","content":"Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":634,"olType":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 11 May 2026 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company (“NewCo”) to advance a specific GPCR-targeted program owned by Nxera. Nxera today announces that, in connection with the closing of a Series A financing undertaken by NewCo, Nxera and a syndicate of leading healthcare and life sciences-focused investors have entered into an investment agreement with NewCo. NewCo will accelerate preclinical studies of a GPCR program against a target discovered using Nxera’s NxWave™ technology platform and advance the program toward global clinical trials. By participating in the Ser...